Medical cannabis: still no executive orders, but a new report is coming soon
The government is buying time, while patients are losing it. The Senate has passed an amendment to the Social Security Financing Bill (PLFSS) calling on the government to submit a report on the rollout of medical cannabis in France.
Another request for a timeline regarding an issue that now has more unfulfilled promises than patients who have legally been treated with cannabis. While the regulations are still pending, the next deadline mentioned by the government is now January.
Yet Another Report to Lift the Ban on Medical Cannabis?
Amendment No. 1675 (revised), sponsored by Socialist Senator Marion Canalès during the Senate’s consideration of the Social Security Financing Bill, was adopted despite two negative opinions—one from the committee and one from the government. Its goal: to obtain a report on the state of’Progress on Medical Cannabis in France, the widespread implementation of which remains pending the publication of regulatory texts.
But behind this request lies, above all, a growing sense of frustration among lawmakers. After all, the French medical cannabis sector has already seen its share of reports, commitments, and timelines—yet the announced deadlines have never been met.
The pilot program began in March 2021. In late 2023, Congress enacted legislation establishing a framework to facilitate the transition to sustainable access to treatment. Nearly three years later, the decrees and orders necessary for its implementation have yet to be issued.
As of March 27, 2024, no new patients may be enrolled in the experimental program. Meanwhile, patients who could benefit from these treatments have no legal means of accessing them through this program—if they do not die first.
Government timelines are consistently being pushed back
The bill was supposed to move forward in 2025, however. After multiple delays, a new government timeline called for regulatory progress before the summer of 2026. During a Senate hearing to review the law on June 30, the minister in charge of Relations with Parliament assured the Senate that the decrees had been drafted, signed and expected after the summer break.
Summer has come and gone. The texts haven't been published. An audition is scheduled for October 20 and 21 before the French National Authority for Health (HAS) was also canceled due to a lack of sufficient regulatory progress.
During the Senate debates, the Minister of Health indicated that the matter might be referred to the Council of State in January, prior to the HAS’s assessment.
January would therefore not even mark the date when treatments become available, but rather a new administrative step before the next one.
«The Powerlessness of Parliamentary Representation»
The debate over the amendment led to a rare consensus among senators, transcending the usual political divides. Marion Canalès denounced a situation that has become untenable for patients suffering from serious conditions, particularly multiple sclerosis, drug-resistant epilepsy, or intractable pain.
Senator Bernard Jomier pointed out that medical cannabis is intended for patients for whom available treatments are insufficient.
Nathalie Goulet spoke about her father, who died of bone cancer after suffering considerable pain and receiving «illegal» pain relief.
Several senators—who are traditionally opposed to requests for parliamentary reports—announced that they would, as an exception, vote in favor of this amendment to denounce administrative inaction.
Even the chairman of the Social Affairs Committee, Philippe Mouiller, while maintaining his opposition in principle, suggested that his colleagues might «forget to vote against it.».
A symbolic vote, with no guarantee that the impasse will be resolved
The adoption of this amendment is, above all, a political statement directed at the government. It does not unblock any executive order, does not impose any timeline, and does not actually bring patients any closer to accessing treatment.
The absurdity of the situation lies here: Parliament has already passed a legal framework for medical cannabis, but now finds itself requesting a report to determine why the government still hasn’t implemented it. Several senators are, in fact, openly pointing to an impasse outside the Ministry of Health.
After five years of experimentation, repeated delays, and a string of unfulfilled promises, it’s hard to believe that another report or yet another timeline will be enough to break the deadlock. The problem is no longer the lack of a roadmap, but the government’s inability to adhere to the ones it has announced itself.
And while the administration racks up missed deadlines, patients continue to wait. January 2027 will not mark their access to treatment, but, at best, another step in a never-ending regulatory process.
-
Business4 weeks ago
Cronos Completes the Acquisition of CanAdelaar for 57.5 million euros
-
Cannabis in Quebec3 weeks ago
Cannabis: What France Could Learn from Quebec, Eight Years After Legalization
-
Cannabis in New Zealand3 weeks ago
Chronic Pain: New Zealand Is Testing Cannabis to Improve Sleep
-
Cannabis in Morocco4 weeks ago
Morocco: Three Cannabis-Based Medications Approved for the Treatment of Epilepsy
-
Cannabis in France3 weeks ago
Dr. Pascal Douek, a tireless advocate for medical cannabis in France, has died
-
Business4 weeks ago
The Brazilian medical cannabis market continues to grow
-
Cannabis in Spain4 weeks ago
Spain: Medical Cannabis Is Coming to About 50 Hospitals
-
Cannabis in France3 weeks ago
Medical cannabis: The Greens introduce two amendments to accelerate its widespread adoption


You must be logged in to post a comment Login